Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) by 26.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 69,075 shares of the company's stock after buying an additional 14,597 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Teva Pharmaceutical Industries were worth $519,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of TEVA. Capital Research Global Investors increased its stake in Teva Pharmaceutical Industries by 11.3% in the 4th quarter. Capital Research Global Investors now owns 132,350,750 shares of the company's stock worth $1,060,109,000 after purchasing an additional 13,474,099 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in Teva Pharmaceutical Industries by 953.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,028,487 shares of the company's stock worth $19,047,000 after purchasing an additional 1,835,952 shares during the period. Bank of Montreal Can increased its stake in Teva Pharmaceutical Industries by 88.4% in the 1st quarter. Bank of Montreal Can now owns 3,811,347 shares of the company's stock worth $35,788,000 after purchasing an additional 1,787,830 shares during the period. Allianz Asset Management GmbH purchased a new position in Teva Pharmaceutical Industries in the 1st quarter worth approximately $15,844,000. Finally, Renaissance Technologies LLC increased its stake in Teva Pharmaceutical Industries by 168.3% in the 1st quarter. Renaissance Technologies LLC now owns 2,589,163 shares of the company's stock worth $24,312,000 after purchasing an additional 1,623,966 shares during the period. 46.22% of the stock is owned by hedge funds and other institutional investors.
Get Teva Pharmaceutical Industries alerts:Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the company. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $9.00 to $10.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 2nd. UBS Group assumed coverage on Teva Pharmaceutical Industries in a research note on Monday, June 13th. They set a "neutral" rating and a $10.00 target price on the stock. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Friday, June 17th. Finally, Bank of America raised Teva Pharmaceutical Industries from a "neutral" rating to a "buy" rating and boosted their target price for the company from $10.00 to $13.00 in a research note on Friday, August 5th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $10.67.
Teva Pharmaceutical Industries Trading Down 2.0 %
NYSE TEVA opened at $7.90 on Monday. The company has a quick ratio of 0.74, a current ratio of 1.11 and a debt-to-equity ratio of 2.07. Teva Pharmaceutical Industries Limited has a twelve month low of $6.78 and a twelve month high of $11.34. The firm has a market capitalization of $8.77 billion, a PE ratio of -8.32, a P/E/G ratio of 3.08 and a beta of 1.27. The stock's 50 day moving average is $9.25 and its 200 day moving average is $8.74.Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last released its earnings results on Tuesday, July 26th. The company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.55 by $0.09. Teva Pharmaceutical Industries had a positive return on equity of 25.68% and a negative net margin of 6.83%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.82 billion. Research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.44 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Teva Pharmaceutical Industries news, CFO Eliyahu Sharon Kalif sold 55,500 shares of the business's stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $10.07, for a total value of $558,885.00. Following the sale, the chief financial officer now directly owns 9,376 shares of the company's stock, valued at $94,416.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, VP David Matthew Stark sold 58,163 shares of the company's stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $9.04, for a total transaction of $525,793.52. Following the transaction, the vice president now directly owns 2,974 shares of the company's stock, valued at $26,884.96. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Eliyahu Sharon Kalif sold 55,500 shares of the company's stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $10.07, for a total value of $558,885.00. Following the transaction, the chief financial officer now directly owns 9,376 shares in the company, valued at $94,416.32. The disclosure for this sale can be found here. Corporate insiders own 0.82% of the company's stock.
Teva Pharmaceutical Industries Profile
(Get Rating)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
Featured Articles
- Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.